<DOC>
	<DOC>NCT02992223</DOC>
	<brief_summary>Evaluate if Y90 Ibritumomab Tiuxetan Radioimmunotherapy in addition to standard high dose chemotherapy followed by autologous stem cell transplant could improve prognosis in patients affected by relapsed/refractory aggressive non Hodgkin lymphoma</brief_summary>
	<brief_title>Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCT</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>High Risk Relapsed/refractory aggressive nonhodgkin lymphoma defined as: Progressive disease Early relapse (within 12 months from response) Recurrent relapse Treated with salvage chemotherapy followed by Y90 Ibritumomab Tiuxetan plus highdose chemotherapy and Autologous stem cell transplant Age &gt; 18 years Previous treatment with Rituximab Written informed consent Patient with no complete data available for collection</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Aggressive B-cell non-Hodgkin Lymphoma</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Zevalin</keyword>
	<keyword>Y90 Ibritumomab Tiuxetan</keyword>
	<keyword>Autologous stem cell transplant</keyword>
	<keyword>BEAM</keyword>
	<keyword>Recurrent</keyword>
</DOC>